March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
4 citations
,
September 1993 in “Steroids” The method accurately measures testosterone metabolites with high sensitivity and low environmental impact.
January 2013 in “Zhonghua linchuang yishi zazhi” Taking finasteride for over a month before surgery reduces blood loss during TURP.
2 citations
,
April 2007 in “Journal of Labelled Compounds and Radiopharmaceuticals” The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.
46 citations
,
January 2005 in “PubMed” Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
13 citations
,
December 2012 in “Canadian Urological Association Journal” 5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
11 citations
,
December 2002 in “Controlled Clinical Trials” Simple methods using DHT levels effectively assess compliance.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
September 2011 in “Urology” Urinary PSA could be an early marker for enlarged prostate.
Taking Finasteride before surgery reduces blood loss and surgery time.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
25 citations
,
March 2004 in “Regulatory Toxicology and Pharmacology” Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
10 citations
,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
January 2011 in “China Modern Doctor” Combining longxuejie and finasteride effectively reduces bleeding during TURP without side effects.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
28 citations
,
November 2003 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The normal human prostate does not significantly affect blood DHT levels.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
PLX, a tomato extract mix, may help treat prostate issues like BPH.
3 citations
,
September 2023 in “Prostate Cancer and Prostatic Diseases” April 2017 in “The Journal of urology/The journal of urology” Finasteride use is linked to a lower risk of bladder cancer, especially in Caucasians and Hispanics.
July 2004 in “Current Urology Reports” April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.